1-866-61-EISAI (1-866-613-4724)

Monday – Friday, 9 am to 6 pm ET

Financial Assistance

Resources to help you manage out-of-pocket expenses for LENVIMA®, including information about the Eisai Assistance Program and the LENVIMA® Patient Assistance Program.

LENVIMA® Savings Programs

LENVIMA® $0 Co-pay Program

The LENVIMA® $0 Co-pay Program offers commercially insured patients a $0 co-pay for each prescription, with a $40,000 annual limit. Enrollment is required for those receiving LENVIMA® from a source other than Accredo or Biologics. Please call the Eisai Assistance Program at 1-866-61-EISAI (1-866-613-4724) for more information.

If you are deemed ineligible, there may be alternate funding options available.

Alternate funding assistance may also be available for those who are not eligible for the LENVIMA®.

*Maximum benefit: The LENVIMA® $0 Co-pay Program provides up to $40,000 per year to assist with the out-of-pocket costs for LENVIMA®. Depending on the insurance plan, your patient could have additional financial responsibility for any amounts over Eisai’s maximum liability.

Eligibility criteria: Good toward the purchase of LENVIMA®

prescriptions. No substitutions permitted. Not available to patients eligible for state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Offer only available to patients with private, commercial insurance. Offer available to MA residents through June 30, 2017. May not be combined with any other coupon, discount, prescription savings card, free trial, or other offer. Void outside the USA and where prohibited by law. Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. Patients, physicians and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the program and complying with any other conditions imposed by insurance carriers on third-party payors. The value of this program is not contingent on any prior or future purchases. This program is solely intended to provide savings on a purchase of LENVIMA®. Use of this program for any one purchase does not obligate the patient to make future purchases of LENVIMA® or any other product. This offer will expire March 31, 2020.

Eisai Assistance Program

The Eisai Assistance Program offers a number of services to facilitate access and reimbursement support, including

  • insurance verification

  • prior authorization information

  • appeal information

  • alternate coverage/funding information

  • Patient Assistance Program (PAP) enrollment

  • expediting product access and minimizing barriers to access

For More Information Contact Us

Eisai Assistance Program

Phone: 1-866-61- EISAI (1-866-613-4724)
Fax: 1-866-57-EISAI (1-866-573-4724)
Monday – Friday, 9am – 6pm ET

Do You Need Assistance?

Programs run by Patient Support Foundations offer financial and educational assistance

What is a Specialty Pharmacy?

Specialty Pharmacies facilitate coverage of LENVIMA®

Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record

+ Expand - Collapse

Indication:

LENVIMA® (lenvatinib) is a prescription medicine that is used to treat certain kinds of cancer.

  • LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer, that can no longer be treated with radioactive iodine and is progressing
  • LENVIMA is used along with another medicine, everolimus, to treat advanced RCC, a type of kidney cancer, after one course of treatment with another anti-cancer medicine

It is not known if LENVIMA is safe and effective in children.

Important Safety Information

LENVIMA may cause serious side effects, including:

  • high blood pressure (hypertension): High blood pressure is a common side effect of LENVIMA and can be serious. Your blood pressure should be well controlled before you start taking LENVIMA. Your health care provider should check your blood pressure regularly during treatment with LENVIMA. If you develop blood pressure problems, your health care provider may prescribe medicine to treat your high blood pressure, lower your dose of LENVIMA, or stop your treatment with LENVIMA
  • heart problems: Call your health care provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
  • problems with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
  • liver problems: LENVIMA may cause liver problems that may lead to liver failure and death. Your health care provider will check your liver function before and during treatment with LENVIMA. Tell your health care provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark, “tea-colored” urine; light-colored bowel movements (stools)
  • increased protein in your urine (proteinuria): Proteinuria is a common side effect of LENVIMA and can be serious. Your health care provider should check your urine for protein before and during your treatment with LENVIMA. If you develop protein in your urine, your health care provider may decrease your dose of LENVIMA or stop your treatment
  • diarrhea: Diarrhea is a common side effect of LENVIMA and can be serious. If you get diarrhea, ask your health care provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your health care provider or go to the emergency room if you are unable to drink enough liquids and your diarrhea is not able to be controlled
  • kidney problems: Kidney failure has happened with LENVIMA treatment. Your health care provider should do regular blood tests to check your kidneys
  • an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between 2 parts of your gastrointestinal tract (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
  • changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life-threatening. Your health care provider will do blood tests during your treatment with LENVIMA to check the levels of potassium, magnesium, and calcium in your blood, and check the electrical activity of your heart with an ECG
  • low levels of blood calcium (hypocalcemia): Your health care provider will check your blood calcium levels during treatment with LENVIMA
  • a condition called reversible posterior leukoencephalopathy syndrome (RPLS): Call your health care provider right away if you get severe headache, seizures, weakness, confusion, or blindness or change in vision
  • bleeding: LENVIMA may cause serious bleeding problems that may lead to death. Tell your health care provider if you have any signs or symptoms of bleeding during treatment with LENVIMA, including severe and persistent nose bleeds; vomiting blood; red or black (looks like tar) stools; coughing up blood or blood clots; heavy or new onset vaginal bleeding
  • change in thyroid hormone levels: You may have changes in your thyroid hormone levels when taking LENVIMA. Your health care provider may need to change your dose of thyroid medicine while you are taking LENVIMA. Your health care provider should check your thyroid hormone levels every month during treatment with LENVIMA

The most common side effects of LENVIMA in people treated for thyroid cancer include tiredness; joint and muscle pain; decreased appetite; weight loss; nausea; mouth sores; headache; vomiting; rash, redness, itching, or peeling of the skin on your hands and feet; stomach (abdomen) pain; and hoarseness.

The most common side effects of LENVIMA in people treated for kidney cancer include tiredness; joint and muscle pain; decreased appetite; vomiting; nausea; mouth sores; swelling in your arms and legs; cough; stomach (abdomen) pain; trouble breathing; rash; weight loss; and bleeding

LENVIMA may cause fertility problems in males and females. Talk to your health care provider if this is a concern for you.

These are not all the possible side effects of LENVIMA. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit http://www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information.

The information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care professional. All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. Any products discussed herein may have different product labeling in different countries.

CORP-US0106m(1)